| Magnetic
Resonance Spectroscopy Guided Brain Tumor Resection: Differentiation
Between Recurrent Glioma and Radiation Change
Mark
C. Preul, Richard Leblanc, Zografos Caramanos, Reza Kasrai,
Sridar Narayanan and Douglas L. Arnold
Abstract:
Background: It is often difficult to differentiate a recurrent
glioma from the effects of post-operative radiotherapy by means
of conventional neurodiagnostic imaging. Proton magnetic resonance
spectroscopic imaging (1H-MRSI), that allows in vivo measurements
of the concentration of brain metabolites such as choline-containing
phospholipids (Cho), may provide in vivo biochemical information
helpful in distinguishing areas of tumor recurrence from areas
of radiation effect. Patients and Methods: Two patients who
had undergone resection and post-operative radiotherapy for
a cerebral glioma became newly symptomatic. Computed tomographic
(CT) and magnetic resonance imaging (MRI) performed after the
intravenous infusion of contrast material, and in one case,
[18F]fluorodeoxyglucose positron emission tomography
(PET), could not differentiate between the possibilities of
recurrent glioma and radiation effect. The patients underwent
1H-MRSI prior to reoperation and the 1H-MRSI results were compared
to histological findings originating from the same locations.
Results: A high Cho signal measured by 1H-MRSI was seen in areas
of histologically-proven dense tumor recurrence, while low Cho
signal was present where radiation changes predominated. Conclusions:
The differentiation between the recurrence of a cerebral glioma
and the effects of post-operative irradiation was achieved using
1H-MRSI in these two patients whose conventional neurodiagnostic
imaging was equivocal for such a distinction. Where these two
conditions are present, metabolite images from 1H-MRSI, such
as that based on Cho, can be co-registered with other imaging
modalities such as MRI and may also be integrated with functional
MRI or functional PET within a multimodal imaging-guided surgical
navigation system to assure maximal resection of recurrent tumor
while minimizing the risk of added neurological damage.
|
Can.
J. Neurol. Sci. 1998; 25: 13-22
|
|